Clinical Research

Hematology researcher

The Duke Division of Hematology is actively involved in clinical research that translates to advances and improvements in clinical care for patients with benign and malignant blood-related disorders.

Clinical research is being conducted in the following areas:

Current Clinical Trials

Myeloproliferate Neoplasms

Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Identifier: NCT01259856
Principal Investigator: Murat Arcasoy, MD  
Contact: Murat Arcasoy, MD, 919-668-6309,

Correlative Biomarker Study in Patients With Myeloproliferative Disorders Identifier: NCT00665067
Principal Investigator: Murat Arcasoy, MD   
Contact: Murat Arcasoy, MD    919-668-6309  

Apheresis Program

Low Dose Rituximab in Thrombotic Thrombocytopenic Purpura Identifier: NCT01554514
Principal Investigator: Ara Metjian, MD
Contact: Betty H Thames, RN, BSN    919-681-9564     

Safety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathies Identifier: NCT02222545
Principal Investigator:
Contact: Angela Braswell (Pager) 970-6134

Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura (HERCULES) Identifier: NCT02553317
Principal Investigator:
Contact: Kristine Byrne 919-681-2668

Hemostasis and Thrombosis

Genetic Risk Factors Associated With Antiphospholipid Antibody Syndrome (APS) Identifier: NCT00482794
Principal Investigator: Thomas L. Ortel, MD, PhD  
Contact: Thomas L. Ortel, MD, PhD, 919-684-5350 - 

EINSTEIN Junior Phase III: Oral Rivaroxaban in Children With Venous Thrombosis (EINSTEIN Jr) Identifier: NCT02234843
Principal Investigator: 
Contact: Shelia Lambert-Adams 919-970-0654

A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients (MARINER) Identifier: NCT02111564
Principal Investigator: Carmelo Graffignino/Thomas Ortel
Contact: Betty Thames - 970-0331

Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A Identifier: NCT02610127
Principal Investigator: 
Contact: Kristen Mcgill 919-681-3565

Phase 1 Pediatric Pharmacokinetics/Pharmacodynamics (PK/PD) Study Identifier: NCT02303431
Principal Investigator:
Contact: Kristine Byrne 919-681-2668

An Observational Cohort Study of the Safety and Efficacy of Fibrinogen Concentrate, Human (FCH) in Subjects With Congenital Fibrinogen Deficiency Identifier: NCT02427217
​Principal Investigator:

Sickle Cell Disease

A Phase II Trial of Regadenoson in Sickle Cell Anemia Identifier: NCT01788631
Principal Investigator: Marilyn J Telen, MD
Contact: Marilyn Telen, MD  - 919-684-5378 -     

Apixaban in Patients With Sickle Cell Disease Identifier: NCT02179177
Principal Investigator: Nirmish Shah, MD
Contact: Sheila Lambert-Adams 970-0654

Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease Identifier: NCT02187003
Principal Investigator:
Contact: Angela Braswell 919-970-6134, Marilyn Telen, MD 919-684-5378